- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16:35 | A small buyout deal gives a penny-stock biotech a boost and a second chance | ||
| 16:35 | News briefing: SpringWorks, Jazz exchange $35M and PTSD drug; Dr. Reddy's says cyberattack was ransomware | ||
| 15:35 | Former Allergan program posts positive topline PhIII results in farsightedness in an R&D win post-AbbVie merger | ||
| 15:35 | Bristol Myers' Richard Hargreaves pays $70M to launch a neurodegeneration alliance with a star player in the machine learning world | ||
| 15:35 | RemeGen readies $514M IPO as HKEX adds jewel to the crown | ||
| 14:35 | Arena's Amit Munshi spins out his neuro sub into a biotech startup, with $56M for the baptism | ||
| 13:35 | Chinese rare disease player inks first deal around narcolepsy drug Wakix after grabbing $80M to build an ecosystem | ||
| 12:35 | Eli Lilly lines up a blockbuster deal for Covid-19 antibody, right after it failed a NIAID trial | ||
| 12:35 | Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer | ||
| 12:35 | Scientists warn Americans are expecting too much from a coronavirus vaccine | ||
| 10:35 | Covid-19 roundup: Sanofi and GSK pledge 200M vaccine doses for a global distribution campaign | ||
| 10:35 | Novartis CEO Vas Narasimhan signs off on a $231M deal to try something new in the R&D fight against SARS-CoV-2 | ||
| Di | A dark horse entrant into the spinal muscular atrophy field doubles its value on some PhII data | ||
| Di | News briefing: Novartis' Zolgensma hits blockbuster status, triggering $80M milestone; Caris raises $310M for genomic profiling expansion | ||
| Di | Sobi bets $250M cash, about $1B in milestones for rights to a C3 therapy being pushed through 5 pivotal trials | ||
| Di | A month after Illumina's big Grail buyout, Exact Sciences scoops up liquid biopsy rival Thrive for a relative bargain | ||
| Di | Bayer follows R&D deal spree by raiding Roche's cancer group for its new research chief | ||
| Di | After falling behind the leaders, dissed by some experts, biotech showman Patrick Soon-Shiong finally gets his Covid-19 vaccine ready for a trial. But can it live up to the hype? | ||
| Di | Where's the Pfizer efficacy readout? Pharma giant says no interim analysis done yet on Covid-19 vaccine | ||
| Di | The disruptors at EQRx have their eyes on the PD-(L)1 market - teeing up $150M cash to grab 2 backbone therapies from China | ||
| Di | Patrick Soon-Shiong steps down as CEO of NantKwest, a linchpin of his 'Cancer Moonshot' | ||
| Di | Covid-19 roundup: Medicare and Medicaid recipients could receive vaccines for free - report | ||
| Di | Researchers shutter Eli Lilly Covid-19 study after monitors flag their antibody as a flop for hospitalized patients - but EUA hunt continues | ||
| Mo | Three years into a PhIII program for a failed Duchenne MD drug, Catabasis hauls down the flag and admits defeat | ||
| Mo | Ultragenyx slams the brakes on rare disease study after all 5 patients are hit with a serious setback |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
